Form 4: Achieve Life Sciences CFO Acquires Stock Options and Performance Restricted Stock Units

Achieve Life Sciences' Chief Financial Officer, Mark Oki, has acquired 72,000 stock options and 168,000 performance-based restricted stock units.

Summary

• Mark Oki, the Chief Financial Officer of Achieve Life Sciences, acquired 72,000 common stock options with an exercise price of $4.52 on December 6, 2024.
• These options vest over a period of 36 months, with one-third vesting on the first anniversary of December 5, 2024, and the remainder vesting monthly over the following 24 months.
• Oki also acquired 168,000 performance-based restricted stock units (PRSUs) on the same date.
• The PRSUs will vest upon the achievement of certain milestones, and will lapse entirely if none of the milestones are met.
• The options expire on December 6, 2034, and the PRSUs expire on December 6, 2028.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align management's interests with shareholders. There are no negative implications.

Positives

• The acquisition of stock options and PRSUs by the CFO aligns his interests with those of the shareholders.
• The vesting schedule of the options and the performance-based nature of the RSUs incentivize long-term value creation and achievement of company goals.

Risks

• The PRSUs will lapse if the performance milestones are not achieved, which could impact the CFO's compensation.

Future Outlook

The vesting of the stock options and PRSUs is contingent on time and performance milestones, indicating a focus on long-term growth and achievement of company objectives.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Granting stock options and performance-based restricted stock units is a common practice among publicly traded companies to incentivize executives.
• The vesting schedule of one-third after one year and the remainder over 24 months is a typical vesting schedule for stock options.
• Performance-based restricted stock units are also a common method to align executive compensation with company performance, similar to practices at companies like Amgen and Gilead Sciences.

Stakeholder Impact

• Shareholders may view this positively as it aligns the CFO's interests with the company's long-term success.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, performance restricted stock units, PRSU, insider trading, executive compensation, vesting, Achieve Life Sciences, ACHV, Mark Oki